This project is designed to test three hypotheses with regard to the development of humanized monoclonal antibody (huAb)-based therapies of epithelial cancers: (1) Can mAbs against restricted differentiation antigens be used for selective delivery of therapeutic amounts of radioisotopes or toxic agents? (ii) Can mAbs with biological effector functions (including immune tumor cell lysis) focus the destructive effect of an inflammatory reaction at the tumor site? (iii) Can restricted tumor stromal antigens such as fibroblast activation protein (FAP) and endosialin serve as therapeutic targets in epithelial cancers? Past studies with mouse mAbs have identified several antigenic systems of colon, kidney, and breast cancers that hold promise for immunotherapeutic approaches because some are highly expressed in tumor tissues but show only limited normal tissue expression; some are efficient targets for complement-mediated cytotoxicity; and some have shown selective tumor targeting in phase I biodistribution/dosimetry studies in patients. However, the clinical utility of mouse mAbs in the therapy of epithelial cancers is limited by the induction of human antimouse antibody (HAMA) responses that prevent prolong and/or repeat treatment. The use of chimeric (chAb) and humanized (huAb) versions of available mAbs offers a powerful method for overcoming these shortcomings and for exploring the therapeutic potential of mAb conjugates with radioisotopes or drugs and mAbs with intrinsic cytotoxic or inflammatogenic properties.
Aim I focuses on the use of two mAbs, huAb A33 and chAb G250, against highly restricted antigens of colon and kidney cancers as carriers for radioisotopes and drugs. Moreover, A33 serves as a prototype for target antigens with prominent internalization characteristics, allowing the use of mAb-conjugates with Auger electron-emitting isotopes and drugs with intracellular sites of action.
Aim II explores the use of an immune cytotoxic anti-Le/y mAb, huAb S193, in patients with colon and breast cancer, and initial evaluation of an immune cytotoxic IgM, mAb F31, in patients with kidney cancer. (The assessment of immune cytotoxic and inflammatogenic effects in these patients will be conducted in conjunction with Projects by Drs. Scheinberg and Houghton.) Aim III represents a novel concept for the imaging and therapy of epithelial cancers that employs huAbs against restricted antigens of reactive tumor stromal fibroblasts (huAb F19, anti-FAP) and tumor capillary endothelial cells (huAb FB5, anti-endosialin). These targets are particularly attractive because the stromal compartment is critical for the growth of epithelial cancers, and stromal targets may be readily accessible to circulating mAbs. The proposed phase I and II trials will follow a general study design previously developed for mouse mAbs, with emphasis on biodistribution studies (external imaging, biopsy-based dosimetry, autoradiography) and dosimetry development (in conjunction with the Nuclear Medicine Core). These studies may lead to safe and effective immunotherapies for patients with epithelial cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA033049-15
Application #
6269154
Study Section
Project Start
1998-01-30
Project End
1998-12-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
15
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
McDevitt, Michael R; Thorek, Daniel L J; Hashimoto, Takeshi et al. (2018) Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nat Commun 9:1629
Casey, E; Bournazos, S; Mo, G et al. (2018) A new mouse expressing human Fc? receptors to better predict therapeutic efficacy of human anti-cancer antibodies. Leukemia 32:547-549
Budhu, Sadna; Schaer, David A; Li, Yongbiao et al. (2017) Blockade of surface-bound TGF-? on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. Sci Signal 10:
Alidori, Simone; Thorek, Daniel L J; Beattie, Bradley J et al. (2017) Carbon nanotubes exhibit fibrillar pharmacology in primates. PLoS One 12:e0183902
Scheinberg, David A; Grimm, Jan; Heller, Daniel A et al. (2017) Advances in the clinical translation of nanotechnology. Curr Opin Biotechnol 46:66-73
Weber, Daniela; Jenq, Robert R; Peled, Jonathan U et al. (2017) Microbiota Disruption Induced by Early Use of Broad-Spectrum Antibiotics Is an Independent Risk Factor of Outcome after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 23:845-852
Mathias, M D; Sockolosky, J T; Chang, A Y et al. (2017) CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra-low density cancer epitopes. Leukemia 31:2254-2257
Chang, Aaron Y; Gejman, Ron S; Brea, Elliott J et al. (2016) Opportunities and challenges for TCR mimic antibodies in cancer therapy. Expert Opin Biol Ther 16:979-87
Alidori, Simone; Akhavein, Nima; Thorek, Daniel L J et al. (2016) Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. Sci Transl Med 8:331ra39
Alidori, Simone; Bowman, Robert L; Yarilin, Dmitry et al. (2016) Deconvoluting hepatic processing of carbon nanotubes. Nat Commun 7:12343

Showing the most recent 10 out of 289 publications